Literature DB >> 18473883

Inhibition of efflux of quinolines as new therapeutic strategy in malaria.

Maud Henry1, Sandrine Alibert, Christophe Rogier, Jacques Barbe, Bruno Pradines.   

Abstract

Plasmodium falciparum is one of the most lethal parasite responsible for human malaria. Until now, the only one solution to counter malaria is the use of antimalarial drugs. Unfortunately, the extensively use of drugs, such as quinolines (i.e. chloroquine, quinine or mefloquine), have led to the emergence of drug resistance. Chloroquine and probably other quinolines act in interfering in the detoxification of hematin in the digestive vacuole. Quinolines are accumulated in P. falciparum digestive vacuole and the accumulation varies from a susceptible strain to a resistant one. Nevertheless, the mechanisms of quinoline resistance are still investigating. Genetic polymorphisms in some strains have been linked to drug resistance. The modifications observed are mutations on genes that encode transport proteins localized in the membrane of digestive vacuole. Three transporters were involved in quinoline resistance: PfCRT (Plasmodium falciparum chloroquine resistance transporter), Pgh1 (P-glycoprotein homologue 1) and PfMRP (Plasmodium falciparum multidrug resistance protein). They could be involved in accumulation or efflux mechanisms of drugs. In order to understand their role in resistance, localization, encoding gene structure, protein structure and endogenous function of these three transporters are reported. Some molecules that have no intrinsic antimalarial effect have been shown to reverse drug resistance when they are combined to chloroquine, quinine or mefloquine. These molecules are a solution to counter resistance but also they are precious tools to elucidate the resistance mechanisms. The molecules that have already shown a capacity to reverse chloroquine, quinine or mefloquine resistances were reported. Some of them could act on one of the three transporters involved in drug resistance, by confirming their role in quinoline resistance. Here we summarize the main elements of quinoline resistance and reversion of quinoline resistance related to malaria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473883     DOI: 10.2174/156802608783955593

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

1.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

2.  In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.

Authors:  Aurélie Pascual; Maud Henry; Sébastien Briolant; Serge Charras; Eric Baret; Rémy Amalvict; Emilie Huyghues des Etages; Michel Feraud; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

4.  4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.

Authors:  Igor M Opsenica; Mikloš Tot; Laura Gomba; Jonathan E Nuss; Richard J Sciotti; Sina Bavari; James C Burnett; Bogdan A Solaja
Journal:  J Med Chem       Date:  2013-07-12       Impact factor: 7.446

5.  Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.

Authors:  Véronique Parquet; Sébastien Briolant; Marylin Torrentino-Madamet; Maud Henry; Lionel Almeras; Rémy Amalvict; Eric Baret; Thierry Fusaï; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

6.  Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Raymond Bercion; Sébastien Briolant; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

7.  Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum.

Authors:  Bruno Pradines; Sébastien Briolant; Maud Henry; Claude Oeuvray; Eric Baret; Rémy Amalvict; Eric Didillon; Christophe Rogier
Journal:  Malar J       Date:  2010-11-25       Impact factor: 2.979

8.  A whole cell pathway screen reveals seven novel chemosensitizers to combat chloroquine resistant malaria.

Authors:  Jun-Hong Ch'ng; Sachel Mok; Zbynek Bozdech; Martin James Lear; Aicha Boudhar; Bruce Russell; Francois Nosten; Kevin Shyong-Wei Tan
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

10.  Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014.

Authors:  Agathe Boussaroque; Bécaye Fall; Marylin Madamet; Khalifa Ababacar Wade; Mansour Fall; Aminata Nakoulima; Khadidiatou Ba Fall; Pierre Dionne; Nicolas Benoit; Bakary Diatta; Yaya Diemé; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2016-07-07       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.